Abstract
A modified model of the epidemic under conditions of mass vaccination was developed. A comparison of the model results with statistical observations in Israel shows good agreement.
Model calculations are performed on the efficacy of limiting the development of an epidemic by both lockdown and vaccination. Mass vaccination of the population is the most radical method of limiting the growth of the epidemic. The introduction of a lockdown cannot completely prevent the development of an epidemic. The likelihood of the emergence of new strains of the virus is assessed. Without vaccination, the probability of more than two new virus strains per year affecting the epidemic growth process is found to be about 60%. A controlled calculation was made of the effect of the timing of changes in lockdown conditions during the vaccination period on the development of the epidemic. It was particularly shown that the cancellation of the lockdown together with the start of vaccination did not reduce the maximum number of new infections. A controlling calculation was made of the effects of gradually cancelling lockdown. On the basis of these calculations, it is possible to assess the development of the epidemic in different variants of partial lockdown cancellation.
Three dimensionless complexes, made up of the intensities of transmission, vaccination and lockdown restrictions, are found to determine the epidemic’s development.
The intensity of the coronavirus epidemic depends on climatic characteristics, in particular air temperature and the UV index. A relationship is given to estimate the influence of these factors on infection growth.
The way forward for further development of the model is outlined. The immediate goal of modifying the model is to use it for each age group in the population and to find out the links between vaccination rates and the psychological state of the population, i.e. people’s readiness for mass vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
[1] Brauer, F., Castillo-Chavez, C., & Feng, Z. (2019). Mathematical models in epidemiology (Vol. 32). New York: Springer.
[2] Groendyke, C., & Combs, A. (2020). Modifying the network-based stochastic SEIR model to account for quarantine. arXiv preprint arXiv:2008.01202.
[3] Below, D., & Mairanowski, F. (2020). Prediction of the coronavirus epidemic prevalence in quarantine conditions based on an approximate calculation model. medRxiv.
[4] Below, D., Mairanowski, J., & Mairanowski, F. (2020). Checking the calculation model for the coronavirus epidemic in Berlin. The first steps towards predicting the spread of the epidemic. medRxiv.
[5] Below, D., Mairanowski, J., & Mairanowski, F. (2021). Analysis of the intensity of the COVID-19 epidemic in Berlin. Torwards an universal prognostic relationship. medRxiv.
[6] Below, D., Mairanowski, J., Mairanowski F. (2021) Comparative analysis of the spread of the COVID 19 epidemic in Berlin and New York City based on a computational model. https://www.medwinpublishers.com/PHOA
[7] Below, D., Mairanowski, J., Mairanowski F. (2021). Development of the COVID-19 epidemic model: calculations for a mutating virus. https://medwinpublishers.com/JQHE/
[8] Statistics and Research: Coronavirus (COVID-19) Vaccinations (2021). https://ourworldindata.org/covid-vaccinations
[9] List of countries and dependent territories of the World by population (2021). https://countrymeters.info/en/list/List_of_countries_and_dependent_territories_of_the_World_by_population
[10] Moozhipurath, R. K. (2020). Role of Weather Factors in COVID-19 Death Growth Rates in Tropical Climate: A Data-Driven Study Focused on Brazil. medRxiv.
[11] Notari, A., & Torrieri, G. (2020). COVID-19 transmission risk factors. arXiv preprint arXiv:2005.03651.
[12] Ilie, P. C., Stefanescu, S., & Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging clinical and experimental research, 32(7), 1195-1198.
[13] Weather Atlas Resources (2021). https://www.weather-atlas.com/en/resources.
[14] Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., … & Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine, 384(15), 1412-1423.
[15] Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., … & Edmunds, W. J. (2021). Estimated transmissibility and impact of SARSCoV-2 lineage B. 1.1. 7 in England. Science, 372(6538).
[16] Vahe Nafilyan, Charlotte Gaughan and Jasper Morgan (2021). Coronavirus and vaccination rates in people aged 70 years and over by socio-demographic characteristic, England: 8 December 2020 to 11 March 2021. Office for National Statistics.
